<DOC>
	<DOC>NCT01029470</DOC>
	<brief_summary>Primary objective: To evaluate the efficacy in terms of oocyte retrieval number of rLH supplement in women with hyporesponse to rFSH after pituitary downregulation. Secondary objective: To further explore the efficacy of rLH supplement in women with hyporesponse to rFSH after pituitary downregulation To evaluate the safety of rLH supplementation in hyporesponse women</brief_summary>
	<brief_title>To Describe the Effect of rhLH Supplementation in Women With Hyporesponse to rhFSH After Pituitary Downregulation</brief_title>
	<detailed_description>Primary endpoint: Number of oocyte retrieved Secondary endpoints: 1. Oestrodial on hCG day (pg/ml) 2. Number of embryos 3. Implantation rate (%) 4. Clinical pregnancy rate (%) 5. Ongoing PR per IVF cycle (%) 6. Abortion rate (%) 7. Ampoules of rFSH 8. FertiQoL score Safety endpoint: adverse events</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Pituitary Diseases</mesh_term>
	<criteria>1. 2040 years old women 2. With menstrual cycles ranged 2435 days, intraindividual variability±3 days 3. Basal FSH &lt;10 IU/L at cycle D2D5 4. 18 &lt; BMI &lt; 30 5. Presence of two ovaries 6. No ovarian stimulation over the past 3 months 7. Signed inform consent form. 1. Polycystic ovarian syndrome 2. rAFS stage ⅢⅣ endometriosis 3. Chromosomal abnormalities, endocrinological and/or autoimmune disorders. 4. More than two previously unsuccessful IVF.</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Luveris</keyword>
	<keyword>hyporesponse</keyword>
	<keyword>pituitary downregulation</keyword>
	<keyword>IVF</keyword>
	<keyword>Infertility women</keyword>
</DOC>